Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,621 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Conflict Clear all
Completed Phase 2 Interventional Results available

A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

NCT05486065
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
101
States / cities
Birmingham, Alabama • Banning, California • Chula Vista, California + 83 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 22, 2026, 2:01 AM EDT
Completed Phase 2 Interventional Results available

Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)

NCT06482112
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Liver Disease
Interventions
Efinopegdutide
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
36
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 22, 2026, 2:01 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

NCT04973163
View directory record Official record
Conditions
Solid Tumors, KRAS Mutation
Interventions
BI 1823911, BI 1701963, Midazolam
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
New York, New York • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 22, 2026, 2:01 AM EDT
Recruiting Phase 1 Interventional

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

NCT07290036
View directory record Official record
Conditions
Psoriatic Arthritis, Axial Spondyloarthritis
Interventions
Bimekizumab regimen 1 iv, Bimekizumab regimen 2 iv, Bimekizumab regimen 3 sc
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
30
States / cities
Peoria, Arizona • Apple Valley, California • Covina, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 22, 2026, 2:01 AM EDT
Completed Phase 2 Interventional Results available

Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma

NCT01959412
View directory record Official record
Conditions
Asthma
Interventions
Indacaterol 27.5 mcg, Indacaterol 37.5, Indacaterol 55 mcg, Indacaterol 75 mcg, Indacaterol 150 mcg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
12
States / cities
Huntington Beach, California • Los Angeles, California • Mission Viejo, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 22, 2026, 2:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Comparing Two Different Tablet Formulations Of Bosutinib Under Fed Conditions

NCT01080365
View directory record Official record
Conditions
Healthy
Interventions
SKI-606 (Bosutinib)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Sep 6, 2010 · Synced Oct 22, 2026, 2:01 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)

NCT02323100
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ravicti low dose, Placebo
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Denver, Colorado • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 22, 2026, 2:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparing Two Different Methods to Prescribe Exercise

NCT04286919
View directory record Official record
Conditions
Physical Activity, Health Behavior
Interventions
A Randomized Controlled Trial Comparing the Physical Activity Guidelines for Americans to a New Method of Exercise Prescription Among College Students
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Oct 22, 2026, 2:01 AM EDT
Completed Phase 2 Interventional

Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen

NCT00104377
View directory record Official record
Conditions
Type I Hypersensitivity
Interventions
Grass MATA MPL
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
11
States / cities
Overland Park, Kansas • North Dartmouth, Massachusetts • St Louis, Missouri + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2010 · Synced Oct 22, 2026, 2:01 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors

NCT00684957
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Recombinant Human Growth Hormone, Recombinant Human IGF-1
Drug
Lead sponsor
Columbia University
Other
Eligibility
25 Years to 65 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 22, 2026, 2:01 AM EDT
Completed Not applicable Interventional Results available

Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI

NCT02057081
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Posttraumatic Stress Disorders, Depression
Interventions
Multifamily Group for mTBI for Couples, Group Health Education (GHE)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 22, 2026, 2:01 AM EDT
Completed Phase 2 Interventional Results available

Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

NCT02500316
View directory record Official record
Conditions
Growth Hormone Deficiency (GHD)
Interventions
MOD-4023
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
3 Years to 11 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 22, 2026, 2:01 AM EDT
Withdrawn Phase 3 Interventional

Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women

NCT00984152
View directory record Official record
Conditions
HIV-1 Infections
Interventions
TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily, TDF/FTC + Efavirenz (Atripla) Once-Daily
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 22, 2026, 2:01 AM EDT
Not listed Not applicable Interventional

A Clinical Trial Evaluating Diets for IBS

NCT05831306
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Diet A, Diet B
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 22, 2026, 2:01 AM EDT
Recruiting Not applicable Interventional

The New Beginnings Podcast: Brief Audio Intervention for Parents From Divorced and Separated Families

NCT07529548
View directory record Official record
Conditions
Parent Child Relationship, Parenting Intervention, Parenting Behaviour, Interparental Conflict, Feasibility Study, Acceptability, Appropriateness, Child Mental Health
Interventions
New Beginnings Podcast Program, No Interventions
Behavioral · Other
Lead sponsor
Charla Aubrey Rhodes
Other
Eligibility
8 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 22, 2026, 2:01 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

NCT01289990
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773, Placebo, Sitagliptin 100mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Oct 22, 2026, 2:01 AM EDT
Not listed No phase listed Observational

Effect of Different Intravenous Fluids on Post-operative Chronic Subdural Hematoma Size and Recurrence

NCT03831997
View directory record Official record
Conditions
Chronic Subdural Hematoma
Interventions
Dextrose 5% W/ Sodium Chloride 0.225%
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 22, 2026, 2:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose

NCT03586843
View directory record Official record
Conditions
Obesity
Interventions
JNJ-64565111
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 22, 2026, 2:01 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Characterization of Human Olfactory Amygdala Subregions exp2

NCT07074574
View directory record Official record
Conditions
Changes in Olfactory Behavior Across Different Contexts Associated With Different Amygdala Subregions
Interventions
Present odors to participants while recording brain activity using fMRI
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 22, 2026, 2:01 AM EDT
Withdrawn No phase listed Observational

Markers for Predicting Risk of Breast Cancer in Women of Different Races

NCT02574546
View directory record Official record
Conditions
Breast Cancer
Interventions
Mastectomy
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 22, 2026, 2:01 AM EDT
Recruiting Not applicable Interventional

Patient-reported Outcomes of Donor Site Healing Using Different Palatal Protection Techniques

NCT06892496
View directory record Official record
Conditions
Mucosal Erosion, Gingival Recession
Interventions
Visual Analog scale (VAS) questionnaire, Vacuum-formed retainer (VFR) technique, 3-D printed acrylic resin stent (3DS) technique, Flowable resin composite stent (FRC) technique, Photographs of the patient's palate, Measuring graft dimensions, Chairside Polymer Stent
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 22, 2026, 2:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Differential Metabolism of Dietary Fatty Acids

NCT00059254
View directory record Official record
Conditions
Obesity, Diabetes, Hyperlipidemia
Interventions
Oleic acid (OA), Palmitic Acid (PA)
Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 35 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2005
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 22, 2026, 2:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

NCT02213354
View directory record Official record
Conditions
Avian Influenza
Interventions
MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years to 99 Years
Enrollment
479 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 22, 2026, 2:01 AM EDT
Completed Phase 1 Interventional

The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin

NCT01043510
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin detemir
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 22, 2026, 2:01 AM EDT